Sees “confident” in this target, with revenue anticipated to be driven by the products’ best-in-class attributes, continued new prescription growth, and total prescription growth, which the company is seeing no signs of slowing down in Q3. Guidance taken from Harrow’s (HROW) Investor Day 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HROW:
- Morning Movers: Pharma, truck stocks react to Trump tariff announcements
- Harrow Health Acquires Melt Pharmaceuticals for Expansion
- Harrow enters agreement to acquire Melt Pharmaceuticals
- Harrow to hold analyst and investor day
- Harrow Health’s Strategic Debt Restructuring and Acquisition Propel Buy Rating